IGF-1 LR3

uestion": "What is the difference between IGF-1 and IGF-1 LR3?", "answer": "IGF-1 is a naturally occurring hormone. IGF-1 LR3 is a synthetic analog of IGF-1 that has been structurally modified to have a longer half-life and a reduced binding affinity to IGF binding proteins (IGFBPs). This means IGF-1 LR3 stays active in the body longer and has more free, unbound hormone available to exert its effects compared to native IGF-1."}, {"question": "Is IGF-1 LR3 safe for human use?", "answer": "No, IGF-1 LR3 is a research chemical and is not approved for human therapeutic use by regulatory bodies like the FDA. Its safety profile in humans has not been thoroughly established through clinical trials, and potential side effects, such as hypoglycemia and increased cancer risk, are significant concerns."}, {"question": "How is IGF-1 LR3 administered?", "answer": "In research settings, IGF-1 LR3 is typically administered via subcutaneous (under the skin) or intramuscular (into the muscle) injection. The specific dosing and frequency are not clinically established and are user-directed within research protocols."}, {"question": "What are the primary effects of IGF-1 LR3?", "answer": "The primary investigated effects of IGF-1 LR3 are related to its potent anabolic properties, particularly in muscle tissue. These include enhanced muscle growth (hypertrophy), improved muscle repair and regeneration, and increased protein synthesis. It also has insulin-like effects on metabolism."}, {"question": "Can IGF-1 LR3 lead to hypoglycemia?", "answer": "Yes, IGF-1 LR3 possesses insulin-mimetic properties, meaning it can lower blood glucose levels. This can lead to hypoglycemia, which is a serious side effect characterized by symptoms like dizziness, sweating, and confusion. Monitoring blood sugar levels is crucial if this compound is used in a research setting."}]